PROGRAM MENU

EDUCATIONAL PROGRAM

WORKSHOPS & SYMPOSIA

CONTINUING EDUCATION


Educational Program

THSNA programming is focused on presenting the most current issues in Hemostasis and Thrombosis. The THSNA 2020 program will include on demand access to recorded talks covering four educational tracks as well as live panel discussion sessions, a nursing workshop, digital posters, corporate symposia, and a virtual exhibit hall with commercial booths.

Note that all timea are listed in Eastern Daylight Time (EDT) and any aspect of this program is subject to change.


Tuesday, October 27th

10:00 - 11:35 AM
PLENARY 1: EMBRACING CHANGE: FROM NEW DISCOVERIES TO NEW TREATMENTS TO IMPROVED PRACTICES
Chair/Organizer: Peter Kouides, Cathy Hayward
Virtual Room 1

The opening Plenary of THSNA will showcase discoveries and advances in the fields of thrombosis and hemostasis, with broad perspectives and examples of exciting changes. The expert presenters will cover important basic discoveries and advances that have been enabled by translating discoveries to improve the understanding, diagnosis and care of people with bleeding and thrombotic problems.


1
Opening Remarks
Peter Kouides. THSNA President

2
Anticoagulant stewardship in the era of novel therapeutics
Allison Burnett. University of New Mexico United States

3
Building from Basic Biology to improve diagnosis and care.
David Ginsburg. Howard Hughes Medical Institute, University of Michigan

4
Adapting to New Therapeutic Options: Implications for Clinical Services and Coagulation Laboratories
Rajiv Pruthi. Mayo Clinic
12:15 - 1:15 PM
CORPORATE LUNCH SYMPOSIUM: ASK THE EXPERTS: MANAGING YOUR PATIENTS WITH HEMOPHILIA A IN A VIRTUAL WORLD (LIVE ONLY - NOT RECORDED)
Virtual Room 1

Sponsored By: Genentech, Inc.

Join the experts in hemophilia A as they discuss their experiences of managing patients in a virtual setting. They'll share clinical efficacy and safety data, along with any strategies they used to introduce patients to or manage patients on a subcutaneous prophylaxis. A live Q&A session will be held after to answer any questions. Don't miss out on this opportunity to learn more about a different kind of prophylaxis that may be right for your hemophilia A patients.

The discussion will be led by Shannon Meeks, MD, and feature Michael Callaghan, MD, and Jennifer Maahs, NP.


CORPORATE LUNCH SYMPOSIUM: CO-MORBIDITIES AND PHARMACOKINETICS IN PATIENTS WITH HEMOPHILIA; A CASE-BASED DISCUSSION
Virtual Room 2

Sponsored By: Bayer

An overview of co-morbidities affecting aging in hemophilia, treatment considerations, and the importance of adapting and individualizing therapy with pharmacokinetic management. Discussion of interactive, practical case studies. This program is hosted and presented by Dr. Stacy Croteau and Dr. Craig Kessler.

2:00 - 3:30 PM
HEPARIN-INDUCED THROMBOCYTOPENIA
Chair/Organizer: Gow Arepally , Mihir Bhatt
Virtual Room 1

Welcome to the Live Session. The live stream will appear below at the scheduled time for all logged-in registrants to view. If you see an “Ask a Question” option to the right of the presentation, we highly encourage questions during the live events to facilitate scheduled Q&A portions of the session. Please be sure to get your questions in early. Theater Mode offers you the option to view a larger version of the presentation. Once the session concludes, a recording will be available for on-demand access if this session has been approved for enduring content posting.


1
New approaches to the laboratory diagnosis of HIT
Anand Padmanabhan. Mayo Clinic

2
Role of the Endothelium in HIT Pathogenesis
Lubica Rauova. The Children's Hospital of Philadelphia/University of Pennsylvania

3
Spontaneous HIT: pathogenesis and clinical features
Ted Warkentin. McMaster University
NOT YOUR EVERYDAY BLEEDING
Chair/Organizer: Stephanie Cloutier, Stacy Croteau
Virtual Room 2

Welcome to the Live Session. The live stream will appear below at the scheduled time for all logged-in registrants to view. If you see an “Ask a Question” option to the right of the presentation, we highly encourage questions during the live events to facilitate scheduled Q&A portions of the session. Please be sure to get your questions in early. Theater Mode offers you the option to view a larger version of the presentation. Once the session concludes, a recording will be available for on-demand access if this session has been approved for enduring content posting.


1
Bleeding of Unknown Cause
Julie Jaffray. Children's Hospital of Los Angeles, University of Southern California Keck School of Medicine

3
Beyond the Blood Vessel, Connective Tissue Disorders
Pamela Trapane. University of Florida College of Medicine - Jacksonville

20
Gender Differences in Bleeding & Understanding the Bleeding Tendency in Hemophilia Carriers
Jill Johnsen. Bloodworks and University of Washington
UPDATES ON THE NEW GUIDELINES FOR THROMBOPHILIA TESTING
Chair/Organizer: Kristi Smock, Betsy Van Cott
Virtual Room 3

Welcome to the Live Session. The live stream will appear below at the scheduled time for all logged-in registrants to view. If you see an “Ask a Question” option to the right of the presentation, we highly encourage questions during the live events to facilitate scheduled Q&A portions of the session. Please be sure to get your questions in early. Theater Mode offers you the option to view a larger version of the presentation. Once the session concludes, a recording will be available for on-demand access if this session has been approved for enduring content posting.


1
Guidelines on Testing for Activated Protein C Resistance
Dot Adcock. Laboratory Corporation of America

2
Guidelines on Testing for Protein C and Protein S
Richard Marlar. University of New Mexico

3
Guidelines on Testing for Antithrombin Deficiency
Betsy Van Cott. Massachusetts General Hospital
4:15 - 6:15 PM
AC FORUM WORKSHOP: ANTICOAGULATION FORUM MINI BOOT CAMP
Chair/Organizer: Nathan Clark
Virtual Room 8

Join world experts Dr. Scott Kaatz & Dr. Geoffrey Barnes in a rare opportunity to hear talks from the AC Forum Boot Camp curriculum. In addition, they will be joined by Dr. Nathan Clark for an engaging Q&A panel discussion during the "chalk talk". You can help to shape and drive cutting edge topics about caring for patients on anticoagulants and get your questions answered or cases discussed. Target Audience Description: This activity has been designed to meet the educational needs of physicians, pharmacists, registered nurses, and associated health professionals who work in the field of anticoagulation.


4:15
Introduction
Nathan Clark.

4:20
Top Articles from 2019 You Need to Know
Scott Kaatz.

5:00
Break
.

5:15
COVID 19 & Thrombosis: A Case-Based Discussion
Geoffrey Barnes.

5:45
Live Chalk Talk (full panel)
.

NASCOLA/ISLH WORKSHOP: INTERESTING CASES IN LABORATORY HEMOSTASIS AND THROMBOSIS
Chair/Organizer: Cathy Hayward, Kristi Smock
Virtual Room 2

This joint ISLH/NASCOLA workshop will use a case-based format to highlight important and practical issues in coagulation testing such as strategies, methodologies, interpretation and reporting, and clinical application. The session will be interactive and participant questions and interactive discussion will be encouraged. Target Audience Description: physicians, nurses, laboratory professionals, pharmacists and others.


4:15
Introduction & Welcome
Catherine Hayward, Kristi Smock.

4:20
ISLH Case 1
Catherine Hayward.

4:35
ISLH Case 2
Charles Eby.

4:50
ISLH Case 3
Pall Onundarson.

5:05
NASCOLA case 1
Kristi Smock.

5:15
NASCOLA case 2
Andrew Goodwin.

5:25
NASCOLA case 3
Donna Castellone.

5:35
NASCOLA case 4
Nicole Zantek.

5:45
Q&A with Presenters
.

6:10
Wrap-Up and Conclusion
Catherine Hayward, Kristi Smock.

NURSING WORKSHOP: IMPACT OF ADVANCES IN HEMOSTASIS AND THROMBOSIS ON THE ROLE OF THE NURSE IN THE COORDINATION OF CARE
Chair/Organizer: Chris Guelcher, Lynn Oertel
Virtual Room 1

4:15
Welcome
Chris Guelcher.

4:20
Adolescent trauma, IVC filters and anticoagulation
Christine Guelcher.

4:32
Transition to DOACs, surgery and trauma
Lynn Oertel.

4:44
Catastrophic Antiphospholipid Antibody Syndrome (CAPS): Does It Exist?
Terri Schnurr.

4:56
MIS-C - Thrombosis risk and the role of the APP
Jennifer Meldau.

5:08
Q&A/Panel Discussion
.

5:20
Diagnostic work-up and laboratory challenges
Kim Schafer.

5:32
Adult adherence in the era of Emicizumab prophylaxis
Laurel McKernan.

5:44
Type 3 VWD with an inhibitor - treatment challenges
James Munn. Michigan Medicine

5:56
Q&A/Panel Discussion
.

PLATELET DISORDER SUPPORT ASSOCIATION (PDSA) WORKSHOP: ITP JOURNAL CLUB
Virtual Room 7

A panel of four leading international adult and pediatric specialists in Immune Thrombocytopenia (ITP) will hold an ITP journal club, moderated by James Bussel, MD. Each of the four experts will select and present a recent article of interest, either clinical or laboratory based, over approximately 10-15 minutes. A discussion of each article will follow, including questions from attendees.

7:00 - 8:00 PM
BASIC SCIENCE OF HEMOSTASIS
Virtual Room 4

Evaluating the Role of Single Site Glycan Modification of B-Domain Deleted Factor VIII on Anti-Factor VIII Expression and Antibody Binding
Jasmine C. Ito, John F. Healey, Hunter W. Baldwin, Ernest T. Parker, Shannon L. Meeks , Glaivy Batsuli. Aflac Cancer and Blood Disorders Center of Children, Atlanta, GA, USA

Angiogenic Alterations in Von Willebrand Disease (VWD) as a Possible Cause of Occult Bleeding in the Stomach
Katharina Kaiser1, 2, Stefanie Lehner1, Hanna Allerkamp1, 2, Carsten Detering1, Mahnaz Ekhlasi-Hundrieser1, Christiane Pfarrer2, Mario von Depka1. 1Werlhof Institute, Hannover Germany.2Institute of Anatomy, University of Veterinary Medicine, Hannover Germany

The Role of IgM Reactive to the C1 Domain in the Humoral Immune Response to Factor VIII
Seema R Patel, Jasmine C Ito, Hunter W Baldwin, Courtney Cox, John Healey, Ernest Parker, Shannon L Meeks, Glaivy Batsuli. Aflac Cancer and Blood Disorders Center, Children, Atlanta, GA, USA

BLEEDING DISORDER THERAPY
Virtual Room 3

What to do with patients with Type 3 VWD and VWF inhibitors? Is ITI enough?
Ahmad Al-Huniti, Vanessa Bouskill, Melanie Jackson, Caroline Malcolmson, Alyaa Al Mughairy, Manuel Carcao. The Hospital for Sick Children, Toronto, ON, Canada

An International Multicenter Study of Bevacizumab for Bleeding in Hereditary Hemorrhagic Telangiectasia: The InHIBIT-Bleed Study
Hanny Al-Samkari1, 2, Raj S. Kasthuri3, Joseph G. Parambil4, Hasan A. Albitar5, Carolina Vazquez6, Marcelo M. Serra6, Sophie Dupuis-Girod7, Craig B. Wilsen8, Justin P. McWilliams8, Evan H. Fountain9, James R. Gossage9, Clifford R. Weiss10, Assaf Issachar11, Mary E. Meek12, Miles Conrad13, Vivek N. Iyer5. 1Division of Hematology Oncology, Massachusetts General Hospital, Boston, MA, USA.2Harvard Medical School, Boston, MA, USA.3Division of Hematology/Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.4Respiratory Institute, Cleveland Clinic, Cleveland, OH, USA.5Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, USA.6Department of Internal Medicine, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.7Centre de Reference pour la maladie de Rendu-Osler, Hospices Civils de Lyon, Lyon, France.8Division of Interventional Radiology, Department of Radiology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.9Division of Pulmonary, Critical Care, and Sleep Medicine, Augusta University, Augusta, GA, Augusta, GA, USA.10Russel H. Morgan Department of Radiology and Radiological Science, Division of Interventional Radiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.11Schneider Children, Tel Aviv, Israel.12Department of Radiology, University of Arkansas for Medical Sciences, Little Rock, AR, USA.13Department of Radiology, University of California San Francisco Medical Center, San Francisco, CA, USA

Treatment of Immune Thrombocytopenia with the Spleen Tyrosine Kinase Inhibitor Fostamatinib: Restoring Hemostatic Balance WhileAvoiding a Prothrombotic State
Ivy Altomare1, Vadim Markovtsov2, Leslie Todd2, Dheepika Weerasinghe2, Robert P Numerof2, Sandra Tong2, Esteban Masuda2, James B Bussel3. 1Duke University School of Medicine, Durham, NC, USA.2Rigel Pharmaceuticals, Inc., South SanFrancisco, CA, USA.3New York Presbyterian Hosp. Weill Cornell Medical Center, New York, NY, USA

Efficacy and safety of simoctocog alfa in previously untreated patients with severe haemophilia A: Final results from the NuProtect study
Ri J Liesner1, Ellis J Neufeld2, on behalf of the NuProtect Study Group1. 1Haemophilia Comprehensive Care Centre, Great Ormond Street Hospital for Children, NHS Foundation Trust, London, United Kingdom.2St. Jude Children, Memphis, TN, USA

Use of emicizumab prophylaxis in adult and pediatric hemophilia A patients with and without inhibitors. Single Center experience.
Natalie A. Montanez, Donna Oldfield, Stephanie Gustafson, Joanna Larson, Nidra I. Rodriguez, Neethu Menon, Deborah Brown, Miguel A. Escobar. University of Texas Health Science Center and Gulf States Hemophilia and Thrombophilia Center, Houston, TX, USA

LABORATORY 1
Virtual Room 5

Coagulation and Circulating Heparin Profile in Patients with End-Stage Renal Disease Undergoing Maintenance Hemodialysis
Emily Bontekoe, Arjun Grewal, Jasdeep Bajwa, Nausheen Baig, Melissa Mazariegos, Vinod Bansal, Fakiha Siddiqui, Omer Iqbal, Debra Hoppensteadt, Jawed Fareed. Loyola University Medical Center, Maywood, IL, USA

Assessment of a new chromogenic FVIII assay in severe Haemophilia A plasma containing emicizumab
Annette Bowyer, Steve Kitchen, Richard Wardle, Rhona Maclean. Sheffield Haemophilia and Thrombosis Centre, Sheffield, United Kingdom

The Utilization of DOAC-Stop In Laboratory Investigation Of Lupus Anticoagulant For Patients On Direct oral anticoagulants
Jing Jin1, Chris Pfaffroth1, Trang Vu1, Steven Baker2, James Zehnder2, 3. 1Department of Special Coagulation Clinical laboratory, Stanford Health Care, Palo Alto, CA, USA.2Department of Pathology, School of Medicine, Stanford University, Stanford, CA, USA.3Division of Hematology, School of Medicine, Stanford University, Stanford, CA, USA

The influence of Emicizumab (Emi) on global hemostasis is better measured by thrombin generation assay (TGA) than thromboelastography
Erika J Martin1, Gita V Massey2, Janice G Kuhn1. 1Virginia Commonwealth University, Richmond, VA, USA.2Children, Richmond, VA, USA

Children and young adults manifest severe COVID-19 coagulopathy
William B Mitchell1, Jennifer Davila1, Janine Keenan1, Jenai Jackson1, Adit Tal1, Kerry A Morrone1, Ellen J Silver1, Sarah O'Brien2, Deepa Mawani1. 1Albert Einstein College of Medicine, Bronx, NY, USA.2Nationwide Children, Cincinnati, OH, USA

THROMBOSIS: DIAGNOSIS AND MANAGEMENT
Virtual Room 6

Optimizing Thromboprophylaxis Use in Pediatric Orthopedic Surgery through Implementation of a Venous Thromboembolism Risk Screening Tool
Wyatt MacNevin1, Kedar Padhye2, Yasser Alkhalife2, Victoria Price1, Ron El-Hawary2, Brian R. Branchford3, Sarah Stevens4, Ketan Kulkarni1. 1Division of Pediatric Hematology Oncology, Department of Pediatrics, IWK Health Centre, Halifax, NS, Canada.2Division of Orthopaedics, IWK Health Centre, Halifax, NS, Canada.3Division of Pediatric Hematology/Oncology/Bone Marrow Transplant, Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO, USA.4Department of Anesthesiology, IWK Health Centre, Halifax, NS, Canada

Analysis of Management Strategies Following Slightly Out of Range INRs: Watchful Waiting vs. Any Dose Changes
Hallie B. Remer1, Xiaokui Gu1, Brian Haymart1, Geoffrey D. Barnes1, Mona Ali2, Eva Kline-Rogers1, Tina Alexandris-Souphis1, Jay Kozlowski3, James B. Froehlich1, Vinay Shah4, Greg Krol4, Scott Kaatz4. 1University of Michigan, Ann Arbor, MI, USA.2Beaumont Hospital, Royal Oak, MI, USA.3Detroit Medical Center, Detroit, MI, USA.4Henry Ford Health System, Detroit, MI, USA

Overutilization of Venous Doppler Ultrasonography to Detect Deep Vein Thrombosis in Intensive Care Units
Sophie Samuel1, Thuy Nguyen1, James Beeson1, Thanh Dao1, Liang Zhu2, Louise D McCullough2. 1Memorial Hermann Medical Center, Houston, TX, USA.2Univeristiy of Texas. McGovern Medical School, Houston, TX, USA

Results of the PEGASUS Phase 3 Randomized Trial Demonstrating Superiority of the C3 Inhibitor, Pegcetacoplan, Compared to Eculizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria
Ilene Weitz1, Hillmen Peter2, Szer Jeff3, Alexander Roth4, Britta Hochsmann5, Jens Panse6, Kensuke Usuki7, Morag Griffin2, Jean-Jacques Kiladjian8, Carlos de Castro9, Hisakazu Nishimori10, Mohamed Hamdani11, Temitayo Ajayi11, Antonio Risitano12, Regis Peffault de Latour13, on behalf of PEGASUS investigators . 1Jane Anne Nohl Division of Hematology, Keck-USC School of Medicine, Los Angeles, CA, USA.2Department of Haematology, St James's University Hospital, Leeds United Kingdom.3Department of Clinical Haematology, Peter MacCallum Cancer Center a Royal Melbourne Hospital, Melbourne Australia.4Department of Hematology, University Hospital Essen, University of Duisburg-Essen, Essen Germany.5Institute of Transfusion Medicine, University of Ulm and Institute of Clinical Transfusion Medicine and Immunogenetics, German Red Cross Blood Transfusion Service and University Hospital Ulm, Ulm Germany.6Department of Oncology, Hematologiy, Hemostaseology and Stem Cell Transplantation, University Hospital RWTH Aachen, Aachen Germany.7NTT Medical Center Tokyo, Tokyo Japan.8Centre d'Investigations Cliniques, Hopital Saint-Louis Assistance Publique, Paris France.9Duke University School of Medicine, Durham, NC, USA.10Department of Hematology and Oncology, Okayama University Hospital, Okayama Japan.11Apellis Pharmaceuticals, Waltham, MA, USA.12Hematology and BMT Unit, AORN San Giuseppe Moscati, Avellino Italy.13French Reference Center for Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria, Assistance Publique, Paris France

Prevalence, Trends, Predictors and Outcomes of Portal Vein Thrombosis in Hospitalized Pancreatic Cancer Patients: A Nationwide Inpatient Sample Database Analysis from 1998-2016
Yu Zhao1, Hussam Alhasson1, Peng Cai2, Anas Saad3, Muneer Al-Husseini4. 1Department of Internal Medicine, Rochester Regional Health- Unity Hospital, Rochester, NY, USA.2Department of Mathematical Sciences, Worcester Polytechnic Institute, Worcester, MA, USA.3Department of Cardiology, Cleveland Clinic Foundation, Cleveland, OH, USA.4Department of Internal Medicine, Ascension St John Hospital, Detroit, MI, USA
7:00 - 7:45 PM
VIRTUAL POSTERS - ANTICOAGULATION CLINICS
Virtual Room 1

Welcome to this Virtual Poster Session. You may view any poster by clicking on a presentation below. Note that you may also submit questions directly to the author of any presentation using the “Ask a Question” option. Note that all questions may not receive a response.


VIRTUAL POSTERS - ANTITHROMBOTIC THERAPY
Virtual Room 2

Welcome to this Virtual Poster Session. You may view any poster by clicking on a presentation below. Note that you may also submit questions directly to the author of any presentation using the “Ask a Question” option. Note that all questions may not receive a response.